Brent Saunders (Richard Drew, AP Images)

OcuWho? Star deal­mak­er turned aes­thet­ics czar Brent Saun­ders flips back in­to biotech. But who’s he team­ing up with now?

Brent Saun­ders went on a tear of head­line-blaz­ing deals build­ing Al­ler­gan, merg­ing and re­ar­rang­ing a va­ri­ety of big com­pa­nies in­to one be­fore an M&A pact with Pfiz­er blew up and sent him on a bout of biotech drug deals. That didn’t work so well, so un­der pres­sure, he got his buy­out at Ab­b­Vie — which need­ed a big fran­chise like Botox. And it was no big sur­prise to see him rid­ing the SPAC wave in­to a re­cent $1 bil­lion-plus deal that left him in the ex­ec­u­tive chair­man’s seat at an aes­thet­ics out­fit — now re­dubbed The Beau­ty Health Com­pa­ny — hold­ing a big chunk of the eq­ui­ty.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.